Presentation and mortality of primary biliary cirrhosis in older patients

Similar documents
Primary Biliary Cirrhosis Once Rare, Now Common in the United Kingdom?

R ecent estimates suggest that there are

Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks

The True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE

Primary Biliary Cholangitis

New insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT A

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto

TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

CLINICAL LIVER, PANCREAS, AND BILIARY TRACT. Epidemiology of Primary Biliary Cirrhosis in Victoria, Australia: High Prevalence in Migrant Populations

Diagnosis and Management of PBC

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam

Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

Managing Abnormal Liver Blood Tests in Older People

Hépatopathies auto-immunes

Resident, PGY1 David Geffen School of Medicine at UCLA. Los Angeles Society of Pathology Resident and Fellow Symposium 2013

age, serum levels of bilirubin, albumin, and aspartate aminotransferase

What Is the Real Gain After Liver Transplantation?

ACG Clinical Guideline: Primary Sclerosing Cholangitis

Morning Report Presentation. Sarah Hughes, MD January 11, 2005

Current Concepts in the Management and Treatment of PBC & PSC

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid

Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis

Ocaliva (obeticholic acid tablets)

PBC treatment: the present and future. Maggie Bassendine Professor of Hepatology

An integrated care pathway improves quality of life in Primary Biliary Cirrhosis

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Primary Biliary Cirrhosis at Hospital Kuala Lumpur: A Study of 11 Cases Seen Between

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs

CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease

Primary biliary cirrhosis (PBC) is a progressive cholestatic

Autoimmune hepatitis

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

Incidence of Primary Biliary Cholangitis in a Rural Midwestern Population

URSODIOL FOR PRIMARY SCLEROSING CHOLANGITIS URSODIOL FOR PRIMARY SCLEROSING CHOLANGITIS. Patients

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

Overview of PSC Making the Diagnosis

POST TRANSPLANT OUTCOMES IN PSC

A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature

Putting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)

Autoimmune Liver Diseases

White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers

The Natural History of Small-Duct Primary Sclerosing Cholangitis

Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785

Pediatric PSC A children s tale

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint

Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful?

Primary sclerosing cholangitis (PSC) is a chronic

Jaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD

A Prospective Trial of Colchicine and Methotrexate in the Treatment of Primary Biliary Cirrhosis

OCALIVA (obeticholic acid) oral tablet

Healthy Liver Cirrhosis

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Chronic Cholestatic Liver Diseases

Primary biliary cirrhosis (PBC) is an autoimmune

Primary biliary cirrhosis (PBC) and primary sclerosing

UNIVERSITY OF CALGARY. Epidemiology and outcomes of primary biliary cirrhosis in the Calgary. Health Region: A population-based study

A Case of Well-differentiated Hepatocellular Carcinoma Arising in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score

THE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES

Risk stratification in PBC

The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom

Patterns of abnormal LFTs and their differential diagnosis

Autoimmune Hepatitis in Clinical Practice

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Sarah Landes October 23, 2014

Primary Sclerosing Cholangitis Medical Management

Tratamiento endoscópico de la CEP. En quien como y cuando?

Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease

Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015

Increased prevalence of primary sclerosing cholangitis among first-degree relatives

Patterns of abnormal LFTs and their differential diagnosis

Primary biliary cirrhosis (PBC) is a rare chronic inflammatory CLINICAL LIVER, PANCREAS, AND BILIARY TRACT

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Biomarkers of PSC. Steve Helmke, Ph.D.

Idiopathic adulthood ductopenia manifesting as jaundice in a young male

P rimary biliary cirrhosis (PBC) is a chronic cholestatic liver

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis

Evaluation Process for Liver Transplant Candidates

Is Serum Bilirubin Concentration the Only Valid Prognostic Marker in Primary Biliary Cirrhosis?

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.

Chronic liver disease in an ageing population

Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment

Outcome and Characteristics of Patients on the Liver Transplant Waiting List: Shiraz Experience

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Anaesthetic considerations and peri-operative risks in patients with liver disease

Transcription:

Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET F. BASSENDINE 2,OLIVER F. W. JAMES 1,2 2000, British Geriatrics Society 1 Department of Medicine (Geriatrics), University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK 2 Centre for Liver Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK Address correspondence to: O. F. W. James. Fax: (þ44) 191 222 0723. Email: o.f.w.james@ncl.ac.uk Abstract Objectives: many patients with primary biliary cirrhosis present for the first time aged over 65, but it is unclear whether the disease is different in older patients. We have examined presentation and mortality in relation to age at which primary biliary cirrhosis was first suspected clinically. Design: we identified 1023 patients from our regional primary biliary cirrhosis database with definite or probable primary biliary cirrhosis (689 definite); 397 (39%) presented aged 65. Definite primary biliary cirrhosis was defined as a positive antimitochondrial antibody titre 1/40, abnormal liver enzymes and compatible/diagnostic histology; probable as the presence of two of these indications. Results: there was no difference in presenting clinical features between the older and younger groups. Older patients were significantly less likely than younger to have had liver biopsy (50% vs 78%; P < 0:001). The 1023 patients had been followed for 8561 patient years. Follow-up was shorter (5.9 4 vs 9.8 5.5 years; P < 0:001) in the older group because of higher cumulative mortality (59% vs 33%; P < 0:001). Liver-related deaths were significantly commoner in the older group (18% vs 13%; P < 0:05). The mortality ratio for liver deaths (liver deaths per year of follow-up) was 2.4 times higher in the older group (0.031 vs 0.013). Conclusions: patients with primary biliary cirrhosis who are over and under 65 have similar features on presentation. The annual risk of liver death is 2.4 times higher in those presenting over 65, reaffirming the importance of age as an independent prognostic factor in an unselected primary biliary cirrhosis population. Keywords: autoimmune disease, elderly, liver, primary biliary cirrhosis Introduction Primary biliary cirrhosis (PBC) is an autoimmune liver disease typically presenting in middle-aged women with progressive cholestatic jaundice [1]. It was thought to be a rare disease, often leading to death from liver failure. However, in recent years perception of the condition has changed. PBC is now often diagnosed at an asymptomatic stage, through the detection of either abnormal serum liver biochemistry or autoantibodies. The changing clinical spectrum of PBC results partly from earlier diagnosis and partly from the recognition of antimitochondrial antibody (AMA) as a marker for the disease [2, 3]. Several large series from tertiary referral centres have shown that the mean age of diagnosis is now between 55 and 60 years [4], implying that many patients are over 65 on first presentation. When prognostic markers for PBC have been examined using multivariate analysis, old age is always an adverse risk factor [5]. Furthermore, the dynamic model from the Mayo Clinic has confirmed that increasing age continues to have an independent and adverse effect on prognosis, implying that the disease course in elderly subjects may be more rapid [6]. Conversely, other studies have speculated as to whether PBC is a more benign disease in elderly patients or the same disease presenting later in life [7, 8]. We have examined the features of PBC in patients presenting for the first time at the age of 65 years or over and compared them to features seen in younger subjects. We have also examined mortality, to determine whether or not advanced age carries an adverse prognosis in PBC. Methods Patients in whom a diagnosis of PBC has been considered in North-East England have been entered 305

J. L. Newton et al. into a PBC database. This was established to carry out an epidemiological study of PBC in a stable population, resident in a defined geographical area in northern England (defined by post code) between January 1987 and December 1994. The case-finding methodology for this study has been described previously [9]. Briefly, we (i) included all PBC patients attending the liver clinic at Freeman Hospital, Newcastle, (ii) sought patients from all gastroenterologists in the region, (iii) used the Regional Hospital Information System to identify all patients with biliary cirrhosis (ICD-9 codes 571 6) from the 13 hospitals in the region, (iv) examined autoimmune antibody profiles carried out in the region between 1987 and 1994 and identified those with positive AMA titre 1:40 (209 000 profiles examined 85% of all profiles carried out), and (v) obtained death certificates for patients who died of biliary cirrhosis in the region (ICD-9 codes 571 6) from the Office of National Statistics. In the present study, we also included patients who had been excluded from the epidemiological study because they lived outside the strictly defined study area (but still within the North-East) or because they had died before 1 January 1987 or been diagnosed after 31 December 1994. Thus, this case series includes both patients in the epidemiological study [9] and all other patients from North-East England in whom a diagnosis of PBC was considered between 1968 and December 1995. We examined retrospectively the hospital case records of all patients in whom a diagnosis of PBC was considered. In the patients with no known case records we approached the family general practitioner for information on the patient (n ¼ 20). We invited these patients (by post), to attend the PBC clinic where we took their history, examined them and carried out blood tests. The date a presumed diagnosis of PBC (i.e. date of presentation ) was made was the time at which two of the following three diagnostic criteria were first fulfilled and recorded in case records: (i) positive AMA titre (1:40), (ii) abnormal liver function tests (LFT i.e. bilirubin, serum transaminases, alkaline phosphatase) and (iii) compatible/diagnostic liver histology for PBC. Despite the presence of at least two of the diagnostic criteria entered in the case records, the diagnosis of PBC may not have been considered by the physician responsible for the patient at that time. From the regional database, we identified individuals with definite or probable PBC. A definite diagnosis was defined as the presence of all three diagnostic criteria. Probable PBC was defined as two of the three criteria [10]. We describe those aged 65 at the time of presumed diagnosis as the older group, and those aged <65 as the younger group. We recorded clinical, biochemical and liver histology data for all subjects on the regional PBC database. As biochemical and serological results are from different laboratories and reference ranges may vary, we expressed data as a ratio of the normal range. All liver biopsies were reviewed by one of two histopathologists and classified according to current histological criteria into early (Scheuer stage I/II) and advanced (Scheuer stage III/IV) [11]. Results are expressed as mean (SD) or median. We performed comparisons with the Student s unpaired Table 1. Patients with primary biliary cirrhosis presenting for the first time before or after the age of 65...... No. of subjects 397 626 Men (% total) 42 (11) 60 (10) Primary biliary cirrhosis (% of total) a Definite 200 (50) 489 (78) Probable 197 (50) 137 (22) a Definite primary biliary cirrhosis: compatible histology, antimitochondrial antibody-positive and abnormal liver function tests; probable: two of the above. Figure 1. Proportions of subjects presenting for the first time before (A) (B) and after the age of 65 with symptoms at presentation that were: asymptomatic of liver disease (antimitochondrial antibody-positive, abnormal liver function tests), symptomatic of primary biliary cirrhosis (Sjogren s syndrome, pruritus, weight loss, xanthelasma, fatigue, right upper quadrant discomfort) or complicated symptoms of portal hypertension or liver failure (jaundice, ascites, varices, encephalopathy, hepatorenal syndrome). 306

Primary biliary cirrhosis in older people Table 2. Levels of biochemical markers in subjects presenting with definite or probable primary biliary cirrhosis for the first time before or after the age of 65 Mean ratio of abnormal result (SD) a, by age at presentation......... Definite Probable Definite Probable... Bilirubin 1.7 (1.9) b 1.24 (1) 1.67 (2) b 1.22 (1.5) Albumin 0.97 (0.07) 0.97 (0.08) 0.98 (0.06) 0.98 (0.07) Alkaline phosphatase 4.85 (6.6) b 2.4 (2.3) 4 (3.4) b 2 (1.9) Transaminase 2.25 (2.9) b 1.6 (3) 2.4 (2.6) b 1.4 (1) a Expressed as a ratio to normal: abnormal bilirubin, alkaline phosphatase, transaminases >1, albumin <1. b Ratios are significantly higher in those with a definite diagnosis compared with those with a probable diagnosis (P < 0:05). t-test for parametric variables and the x 2 test and Mann Whitney U test where appropriate. A statistically significant result is when P < 0:05. We obtained ethical permission for the collection of data and development of the database from the joint Newcastle hospitals/university ethical committee and all other ethical committees in the study region. All subjects gave informed consent for inclusion. Results Presentation From the regional database we identified 1023 individuals with definite or probable PBC presenting between 1968 and 1995. Three hundred and ninetyseven presented at or after the age of 65; 626 presented before the age of 65 (Table 1). Six hundred and eighty-nine (67%) had definite PBC. Of the 334 with probable PBC, 297 (89%) were AMA-positive with abnormal LFT but had not had the diagnosis confirmed by liver biopsy, 23 (7%) were AMAnegative but with compatible biopsy and abnormal LFT ( autoimmune cholangiopathy regarded as clinically indistinguishable from PBC [12]) and 14 (4%) were AMA-positive and had compatible liver histology but normal LFT (these patients have an 80% chance of progressing to classical disease [13]). There was no significant difference in the proportions of those presenting with no symptoms or complications of liver disease at the time of presumed diagnosis in the older compared to the younger group (Figure 1). However, significantly more of the younger group had non-specific minor symptoms of PBC (24.5% versus 16.5%). Investigations There were no significant differences in the markers of disease severity at presentation (serum albumin and bilirubin) between those who had presented before or after the age of 65 in either the definite PBC group or the probable PBC group. Neither were there any significant difference in serum alkaline phosphatase concentrations or transaminase between the age groups at presumed diagnosis (Table 2). The older patients were significantly less likely to have had the diagnosis confirmed histologically than the younger group (P < 0:001). Of the 689 who had had liver biopsy, staging details were available in 491 (71%). In those in whom a biopsy was performed (132/ 200: 66% of biopsies in those over 65 at the time of presentation, 359/489: 73% of biopsies in the younger group), the frequency of advanced histological disease (i.e. stage III/IV) was significantly higher in those patients presenting over 65 than in younger patients (P < 0:01). In those who had liver biopsy, when grouped according to age at first presentation, the ratio of the number of those with cirrhotic to precirrhotic disease increased with advancing age (Figure 2). Notwithstanding the lower proportion of patients receiving biopsies in the older group, patients over 65 Figure 2. The ratio of the numbers of individuals with advanced/early primary biliary cirrhosis (cirrhotic/ precirrhotic) by age at first presentation. 307

J. L. Newton et al. Table 3. Histological stage in those who had liver biopsy after presenting with primary biliary cirrhosis for the first time before (n ¼ 489) or after (n ¼ 200) the age of 65...... No. (and %) of subjects Early (stage I/II) 48 (36) 182 (51) Advanced (stage III/IV) 84 (64) a 177 (49) Median time from presumptive to histological diagnosis, months (range) 3 (0 138) 4 (0 195) a Significantly more than in the younger group. at presentation did not wait longer for histological confirmation (Table 3). Mortality We followed the 1023 patients for 8461 patient years. The older group were followed-up for a significantly shorter time mean (SD) 5.9 (4.0) years versus 9.8 (5.5) years for the younger group (P < 0:001) because of the higher cumulative mortality in the patients presenting for the first time at 65 or older (P < 0:001). When considering cause of death (death certificate and case note review), death from liver-related causes was significantly more frequent in the older group (P < 0:05). We calculated mortality ratios using the formula shown in Table 4. In the total groups, the mortality ratio in the younger group was less than half that found for the older group (0.013 versus 0.03). None of the older group had liver transplantation whilst 48 of the younger group received transplants. We recalculated liver-related mortality ratios after excluding the group that received transplants and found that the mortality ratio was no different (0.013 in those <65 who did not undergo transplants versus 0.008 in those who did). Discussion Presentation The two previous studies of PBC in older people have involved small numbers of patients and incomplete follow-up data. The study of Hislop et al. [7] included only seven patients presenting over 70, with mean follow-up of 25 months. Lehmann et al. [8] examined 35 patients who were over 65 at presentation, with mean follow-up around 55 months. In our case series, we examined the presentation of PBC in 1023 patients, 39% of whom were aged 65 or over at the time of presumed diagnosis. We confirm that PBC does not appear to be a different disease in elderly people as symptoms at first presentation are neither more nor less severe in younger than older individuals. Investigations Biochemical measures of severity did not differ between older and younger groups. Fewer of those aged 65 had a definitive diagnosis of PBC (i.e. had had liver biopsy). It may be argued that making a definite diagnosis of PBC in an elderly patient is of little benefit, particularly as there is no treatment of proven benefit for PBC (although ursodeoxycholic acid delays the development of oesophageal varices even in those with stage IV disease [14]). Liver biopsy is a relatively safe procedure in older patients, with no greater mortality than in younger individuals [15]. In our study, we were surprised to find no delay from the time of clinical suspicion to definitive diagnosis in older people who did have a liver biopsy. Perhaps biopsy was performed in older patients with Table 4. Deaths and liver-related mortality ratios a in those presenting with primary biliary cirrhosis primary before or after the age of 65, and in those who had had liver transplantation (none of whom were in the older group)......... Women Men Total Women Men Transplanted Total... No. in group 355 42 397 566 60 48 626 No. (and %) of deaths All causes 209 (59) 25 (60) 234 (59) 185 (33) 22 (37) 10 (21) 207 (33) Liver-related (A) 67 (19) 4 (10) 71 (18) 74 (13) 7 (12) 4 (8) 81 (13) Years of follow-up (B) 2012 209 2221 5845 495 474 6340 Liver-related mortality ratio (A/B) 0.033 0.019 0.031 0.013 0.014 0.008 0.013 a Number of liver-related deaths/total number of years at risk (i.e. sum of years of follow-up). 308

Primary biliary cirrhosis in older people more severe disease, but there was no significant difference in the markers of severity (serum albumin and bilirubin) between older and younger subjects who had liver biopsy. In most instances in which patients (particularly older patients) did not have liver biopsy, it was thought by the responsible clinician that biopsy would not add to the management of their patient. The frequency of advanced-stage disease (Scheuer stage III/IV) where biopsy was performed was significantly higher in those presenting for the first time over the age of 65. This increased proportion of those with advanced disease with advancing age could suggest either that these individuals are presenting later in the same disease or that there is a reduced willingness to consider liver biopsy in those over 65. Mortality It is not surprising that overall mortality was higher in the older group (59% versus 33%) since there are more deaths in the older group from non-liver-related causes. However, we have confirmed other studies that examined independent prognostic variables in smaller groups: in over 1000 PBC patients whom we followed for 8561 years, the liver-related mortality ratio was over twice as great in women presenting over age 65 (3%/ year) than in those presenting below that age (1.3%/ year). There is little clinical evidence to support the idea that this was because older patients had presented with more advanced disease. As with many other diseases, the ability of the ageing organism to withstand the severe stress of advanced liver disease and possible age-related impaired homeostasis may be responsible [16]. Key points Almost 40% of subjects with primary biliary cirrhosis present for the first time at or after the age of 65. Primary biliary cirrhosis should be included in the differential diagnosis in older people with abnormal liver blood tests. The mortality ratio is higher in individuals who present for the first time when they are over 65. References 1. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289: 674 8. 2. Mitchison HC, Bassendine MF, Hendrick A et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986; 6: 1279 84. 3. Metcalf JV, Mitchison HC, Palmer JM et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: 1399 402. 4. James O, Watson AJ, Macklon AF. Primary biliary cirrhosis a revised clinical spectrum. Lancet 1981: 1278 81. 5. Weisner RH, Porayko MK, Dickson ER et al. Selection and timing of transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992; 16: 1290 9. 6. Murtaugh PA, Dickson ER, Van Dam GM et al. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology 1994; 20: 126 34. 7. Hislop WS, Hopwood D, Bouchier IAD. Primary biliary cirrhosis in elderly females. Age Ageing 1982; 11: 153 9. 8. Lehmann AB, Bassendine MF, James OFW. Is primary biliary cirrhosis a different disease in the elderly? Gerontology 1995; 31: 186 94. 9. Metcalf JV, Bhopal RS, Gray J et al. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne. Int J Epidemiol 1997; 26: 830 6. 10. Metcalf JV, Howel D, Bhopal RS et al. Primary biliary cirrhosis epidemiology helping the clinician. Br Med J 1996; 312: 1181 2. 11. Scheuer PJ. Liver Biopsy Interpretation. Baltimore: Williams and Wilkins, 1973. 12. Heathcote J. Autoimmune cholangitis. Gut 1997; 40: 440 1. 13. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OFW. Natural history of primary biliary cirrhosis. Lancet 1996; 348: 1399 402. 14. Lindor KD, Jorgensen RA, Therneau TM et al. Ursodeoxycholic acid delays the onset of oesophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 12: 1137 40. 15. Gilmore IT, Burroughs A, Murray-Lyon IM et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437 41. 16. Shock NW. Ageing and physiological systems. J Chron Dis 1983; 36: 137 42. Received 21 June 1999; accepted in revised form 16 December 1999 309